Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation

Sara A. Byron, Michael G. Gartside, Candice L. Wellens, Mary A. Mallon, Jack B. Keenan, Matthew A. Powell, Paul J. Goodfellow, and Pamela M. Pollock

Abstract

KRAS activation and PTEN inactivation are frequent events in endometrial tumorigenesis, occurring in 10% to 30% and 26% to 80% of endometrial cancers, respectively. Because we have recently shown activating mutations in fibroblast growth factor receptor 2 (FGFR2) in 16% of endometrioid endometrial cancers, we sought to determine the genetic context in which FGFR2 mutations occur. Analysis of 116 primary endometrioid endometrial cancers revealed that FGFR2 and KRAS mutations were mutually exclusive, whereas FGFR2 mutations were seen concomitantly with PTEN mutations. Here, we show that shRNA knockdown of FGFR2 or treatment with a pan-FGFR inhibitor, PD173074, resulted in cell cycle arrest and induction of cell death in endometrial cancer cells with activating mutations in FGFR2. This cell death in response to FGFR2 inhibition occurred within the context of loss-of-function mutations in PTEN and constitutive AKT phosphorylation, and was associated with a marked reduction in extracellular signal-regulated kinase 1/2 activation. Together, these data suggest that inhibition of FGFR2 may be a viable therapeutic option in endometrial tumors possessing activating mutations in FGFR2, despite the frequent abrogation of PTEN in this cancer type. [Cancer Res 2008;68(17):6902–7]

Introduction

Endometrial cancer is the most commonly diagnosed malignancy of the female reproductive tract in the United States. It was estimated that 39,080 new cases of cancer of the uterus were diagnosed and 7,400 women would die of this disease in the United States in 2007 (1). The majority of women presenting with endometrial cancer are surgically cured with a hysterectomy; however, ~15% of women show persistent or recurrent tumors that are refractory to current chemotherapies. For those women with advanced stage, progressive, or recurrent disease, survival is poor as there are no adjuvant therapies proven to be effective. The 5-year survival for patients who have recurred is only 13% (2).

A variety of somatic gene defects have been reported in endometrial carcinoma. Well or moderately differentiated endometrioid endometrial carcinomas account for ~80% of uterine cancers and are characterized by a high frequency of inactivating mutations in PTEN (26–80%), activating KRAS mutations (10–30%), and gain-of-function CTNNB1 (β-catenin) mutations (25–38%) (3). Our laboratory recently reported mutations in fibroblast growth factor receptor (FGFR)2 in 19 of 187 (10%) primary uterine tumor samples (4). Mutations were seen primarily in tumors of the endometrioid histologic subtype (18 of 115, 16%). The majority of the somatic mutations identified were identical to germline-activating mutations in FGFR2 and FGFR3 that cause a variety of craniosynostosis and skeletal dysplasia syndromes (4).

The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of using anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma. Indeed, recent studies have indicated FGFRs hold promise as targets for anticancer therapy. The efficacy of FGFR inhibitors to inhibit cancer cell growth in vitro and in vivo has been investigated in a variety of malignancies, including myeloma (5) and bladder cancer (6), with significant inhibition of cell growth observed after FGFR inhibition.

Here, we present evidence that activating mutations in FGFR2 occur within the context of PTEN inactivation but are mutually exclusive with KRAS mutations in endometrioid endometrial tumors. Using endometrial cancer cell lines expressing mutationally activated FGFR2 and WT or mutant PTEN, we show inhibition of activated FGFR2, either through shRNA knockdown or treatment with a pan-FGFR inhibitor, PD173074, results in cell death, even within the context of PTEN inactivation. Together, these data suggest that FGFR2 may be a viable therapeutic target in endometrial cancer, despite the high frequency of PTEN abrogation in this tumor type.

Materials and Methods

Study subjects and clinical data. Tumor and matched normal tissue samples were collected from hysterectomy specimens from patients being treated for suspected uterine cancer over the period 1993 to 2005. All participants consented to molecular analyses and follow-up as part of a Washington University Medical Center Human Studies Committee approved protocol (HSC 93-0828). Tissue specimens collected for research were evaluated and diagnoses confirmed by experienced gynecologic pathologists. Given our previous observation that FGFR2 mutations are largely restricted to the endometrioid subtype of endometrial cancer (4), our studies were limited to this histologic subtype. The 116 patient specimens analyzed were originally selected to overrepresent cases with tumor microsatellite instability (MSI) and those patients with advanced stage disease (Supplementary Table S1), to assess whether FGFR2 mutations were more common in MSI-positive tumors and whether FGFR2 mutations were restricted to early stage cancer, as has been reported for FGFR3 mutations in bladder cancer (4). Clinical data were extracted from clinic charts, hospital records, and Barnes-Jewish Hospital Oncology Data Services.

MSI typing. Tissue specimens and blood were obtained at the time of surgery, snap frozen, and stored at ~70°C. DNA was prepared from...
neoplastic cellularity (>70%) using proteinase K and phenol extraction or with the DNeasy Tissue kit (Qiagen, Inc.). Matched normal DNA was extracted from peripheral blood leukocytes as previously described (7). Microsatellite analysis was performed as previously described (7) using five National Cancer Institute consensus microsatellite markers (BAT25, BAT26, D2S123, D5S346, and D17S250). Tumors were classified as MSI+ if novel PCR bands were identified in at least two of the five consensus panel markers. Tumors were considered microsatellite stable (MSI−) if there was no evidence of MSI in any marker.

**Sequencing analysis.** Mutation analysis was performed as previously described (4). PCR primer sequences, listed in Supplementary Table S2, were M13 tailed and sequencing performed in two directions.

**Cell culture and reagents.** The MFE296 cell line was purchased from the European Collection of Cell Cultures (Salisbury). AN3CA, HEC1A, Ishikawa, RL952, and KLE were provided by Dr. Paul Goodfellow (Washington University, St. Louis, MO), and lentiviral packaging plasmids were kindly provided by Dr. Matthew Huentelman (Washington University, St. Louis, MO). PD173074 was purchased from Sigma-Aldrich. The KH1-LV lentivector plasmid was kindly provided by Dr. Maria S. Soengas (University of Michigan, Ann Arbor, MI), and lentiviral production and cell transduction was performed as described (9). Greater than 90% transduction efficiency was achieved in each siRNA experiment, as determined by eGFP visualization (data not shown).

**Growth inhibition assay.** Twenty-four hours after infection, cells were plated in 96-well plates at a density of 5,000 cells per well and proliferation assessed on multiple days using the Sulforhodamine B (SRB) assay (Sigma-Aldrich).

**Fluorescence-activated cell sorting analysis.** Cells were transfected with 25 nmol/L nonsilencing siRNA or FGFR2 siRNA X2 using Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, floating and attached cells were collected and analyzed for Annexin staining evaluated at the indicated time points. For U0126 studies, cells

### Table 1. Mutation status of endometrial endometrial tumors

<table>
<thead>
<tr>
<th>Case ID</th>
<th>FGFR2 Mutation</th>
<th>KRAS Mutation</th>
<th>PTEN Mutation</th>
<th>Stage</th>
<th>Grade</th>
<th>MSI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AN3CA</td>
<td>p.[Lys310Arg(+)]Asn550Lys</td>
<td>WT</td>
<td>p.Arg130fsX4</td>
<td></td>
<td></td>
<td>+</td>
</tr>
<tr>
<td>MFE296</td>
<td>p.Asn550Lys</td>
<td>WT</td>
<td>WT</td>
<td></td>
<td></td>
<td>−</td>
</tr>
<tr>
<td>1359</td>
<td>p.Ser252Trp</td>
<td>WT</td>
<td>WT</td>
<td>I</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1574</td>
<td>p.Ser252Trp</td>
<td>WT</td>
<td>p.[Gly44Ala+X7(+)Y68X]</td>
<td>I</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1492</td>
<td>p.[Ser252Trp(+)]Tyr376Cys</td>
<td>WT</td>
<td>p.Arg130Gly</td>
<td>I</td>
<td>1</td>
<td>−</td>
</tr>
<tr>
<td>1484</td>
<td>p.Ser252Trp</td>
<td>WT</td>
<td>p.[Arg130Gly(+)]F56V</td>
<td>III</td>
<td>3</td>
<td>−</td>
</tr>
<tr>
<td>1316</td>
<td>p.Ser252Trp</td>
<td>WT</td>
<td>p.Leu112Val</td>
<td>III</td>
<td>1</td>
<td>−</td>
</tr>
<tr>
<td>1792</td>
<td>p.Ser252Trp</td>
<td>WT</td>
<td>wt</td>
<td>III</td>
<td>1</td>
<td>+</td>
</tr>
<tr>
<td>1482</td>
<td>p.Ser252Trp</td>
<td>WT</td>
<td>p.Thr319X</td>
<td>IV</td>
<td>2</td>
<td>−</td>
</tr>
<tr>
<td>1267</td>
<td>p.Asn550Lys</td>
<td>WT</td>
<td>p.Ala126Asp</td>
<td>II</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1655</td>
<td>p.Tyr376Cys</td>
<td>WT</td>
<td>p.Arg308IleX5</td>
<td>III</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1684</td>
<td>p.Ser373Cys</td>
<td>WT</td>
<td>p.Arg130Gly</td>
<td>I</td>
<td>1</td>
<td>+</td>
</tr>
<tr>
<td>1361</td>
<td>p.Met392Arg</td>
<td>WT</td>
<td>p.Thr319X</td>
<td>I</td>
<td>1</td>
<td>+</td>
</tr>
<tr>
<td>1744</td>
<td>p.Leu548Val</td>
<td>WT</td>
<td>p.[Phe21Ser(+)K66N]</td>
<td>III</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1717</td>
<td>p.Lys660Glu</td>
<td>WT</td>
<td>p.Ser59X</td>
<td>I</td>
<td>2</td>
<td>−</td>
</tr>
<tr>
<td>1272</td>
<td>c.128+2A&gt;C</td>
<td>WT</td>
<td>WT</td>
<td>I</td>
<td>1</td>
<td>−</td>
</tr>
<tr>
<td>1289</td>
<td>p.Thr762fsX3</td>
<td>WT</td>
<td>p.Gly12Asp</td>
<td>I</td>
<td>3</td>
<td>+</td>
</tr>
<tr>
<td>1284</td>
<td>WT</td>
<td>p.Gly12Asp</td>
<td>p.[Arg130Gly(+)]Gly165Arg</td>
<td>II</td>
<td>1</td>
<td>+</td>
</tr>
<tr>
<td>1606</td>
<td>WT</td>
<td>p.Gly12Asp</td>
<td>p.Val191GlyfsX7</td>
<td>I</td>
<td>1</td>
<td>−</td>
</tr>
<tr>
<td>1856</td>
<td>WT</td>
<td>p.Gly12Asp</td>
<td>wt</td>
<td>I</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1411</td>
<td>WT</td>
<td>p.Gly12Ala</td>
<td>p.[Arg130Gly(+)]Gly165Arg</td>
<td>III</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1966</td>
<td>WT</td>
<td>p.Gly12Ala</td>
<td>p.[Arg130X(+)]Ala148IleX3</td>
<td>III</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1393</td>
<td>WT</td>
<td>p.Gly12Cys</td>
<td>p.Ile4HisfsX5</td>
<td>III</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1599</td>
<td>WT</td>
<td>p.Gly12Val</td>
<td>p.[Arg130Gly(+)]Gln171X</td>
<td>III</td>
<td>2</td>
<td>+</td>
</tr>
<tr>
<td>1873</td>
<td>WT</td>
<td>p.Gly12Val</td>
<td>p.V290X</td>
<td>I</td>
<td>1</td>
<td>+</td>
</tr>
<tr>
<td>1656</td>
<td>WT</td>
<td>p.Gly12Val</td>
<td>p.Gly251ValfsX5</td>
<td>I</td>
<td>1</td>
<td>−</td>
</tr>
<tr>
<td>1664</td>
<td>WT</td>
<td>p.Gly12Asp</td>
<td>p.Tyr16LeufsX27</td>
<td>III</td>
<td>1</td>
<td>−</td>
</tr>
<tr>
<td>1287</td>
<td>WT</td>
<td>p.Gly13Asp</td>
<td>p.[H122Y(+)]Ala126Ser</td>
<td>III</td>
<td>1</td>
<td>−</td>
</tr>
<tr>
<td>1576</td>
<td>WT</td>
<td>p.Gly13Asp</td>
<td>p.Arg130Gln</td>
<td>I</td>
<td>2</td>
<td>+</td>
</tr>
</tbody>
</table>

**NOTE:** Numbering relative to FGFR2 protein sequence NP_075259.2, KRAS protein sequence NP_203524.1, and PTEN protein sequence NP_000305.3.
were treated with 25 μmol/L UO126 (Sigma-Aldrich) and Annexin staining evaluated 72 h after treatment. For cell cycle analysis, cells were treated with 1 μmol/L PD173074 and, 72 h later, were stained with propidium iodide as described (10). Cell cycle analysis was performed using ModFit software (Verity Software House, Inc.).

Immunoprecipitation and Western blot analysis. For PD173074 studies, cells were starved overnight in 0.2% fetal bovine serum (FBS) and then incubated with 1 μmol/L PD173074 for 0 to 72 h. For shRNA studies, 24 h after lentiviral transduction, cells were starved overnight in 0.2% FBS and then lysates collected. For p-FGFR2 and p-ERK1/2 studies, cells were starved overnight in 0.2% FBS, pre-treated with 1 μmol/L PD173074 for 1 h, and then stimulated with 1 μmol/L FGF7 and 10 μg/mL heparin for 5 min. Five hundred micrograms of AN3CA lysate were immunoprecipitated with 2 μg of a FGFR2-specific antibody (Bek C-17; Santa Cruz Biotechnology, Inc.), and Western blot analysis was performed using a phospho-specific FGFR antibody (pFGFR Tyr653/654; Cell Signaling Technology). The Western blot was then stripped and reprobed for total FGFR2 (Bek C-17), pFGFR (Tyr653/654), pFRS2α (Tyr197), AKT, and extracellular signal-regulated kinase (ERK)1/2 antibodies were purchased from Cell Signaling Technology, and total FGFR2 (BekC17) and FRS2α antibodies were from Santa Cruz Biotechnology, Inc.

Statistical analysis. Statistical analyses were performed using GraphPad Prism version 4.0 for Macintosh (GraphPad Software). IC₅₀ values were calculated by dose-response analysis using nonlinear regression of sigmoidal dose-response with variable slope. All P values were considered significant when P value is <0.05. Data were expressed as mean ± SE.

Results

Patterns of FGFR2, PTEN, and KRAS mutations in primary endometrial cancers. Given that PTEN and KRAS mutations are common in endometrioid endometrial cancer, and as FGFRs signal through the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI3K) pathways, we first sought to determine whether FGFR2 mutations occurred in tumors that harbor gain-of-function mutations in KRAS and/or loss-of-function mutations in PTEN. We sequenced all 9 exons of PTEN and exon one of KRAS in 116 endometrioid endometrial tumors for which we knew the FGFR2 mutation status. Due to the limiting amount of DNA available, we only sequenced exon one of KRAS, as mutations in exon one account for >96% of KRAS mutations in endometrioid endometrial cancer. Given the KRAS mutation status, we sequenced PTEN and exon one of KRAS in 116 endometrioid endometrial tumors for which we knew the FGFR2 mutation status. Due to the limiting amount of DNA available, we only sequenced exon one of KRAS, as mutations in exon one account for >96% of KRAS mutations in endometrioid endometrial cancer.4 KRAS mutations were identified in 12% (15 of 116) of tumors (Supplementary Table S1). Activating mutations in FGFR2 and KRAS were mutually exclusive (Table 1). Of note, one tumor possessed a frameshift mutation in FGFR2 (2290-91 del CT) and contained a KRAS (2290-91 del CT) and contained a KRAS mutation. However, as the pathogenic nature of this FGFR2 mutation is unknown, we concluded that activating mutations in FGFR2 were mutually exclusive with activating mutations in KRAS. Mutation analysis revealed PTEN mutations in 70% (82 of 116) of tumors (Supplementary Table S1). Of those tumors with FGFR2 mutations, 77% (14 of 18) also carried a PTEN mutation (Table 1), demonstrating that mutations in FGFR2 frequently occur alongside PTEN mutations in endometrioid endometrial tumors. As previously reported (11), PTEN mutations also occur alongside KRAS mutations (Table 1).

shRNA knockdown of FGFR2 induces cell death in endometrial cancer cells, despite PTEN inactivation. Given the occurrence of activating FGFR2 mutations within the context of PTEN inactivation in endometrial cancer and the known role of

http://www.sanger.ac.uk/genetics/CGP/cosmic
the PI3K/AKT pathway in promoting cell survival, we sought to determine whether inhibition of FGFR2 could induce cell death in the presence of PTEN inactivation. AN3CA and MFE296 endometrial cancer cells were selected as models for these studies. AN3CA cells reflect the majority (~82%) of primary tumors with activating FGFR2 mutations, as these cells carry an activating mutation in the kinase domain of FGFR2 (N550K) and exhibit PTEN abrogation. AN3CA cells have mutations in both PTEN alleles and do not express PTEN (Supplementary Fig. S1). MFE296 cells model the ~18% of primary tumors with FGFR2 mutations that were WT for PTEN, as these cells express mutationaly activated FGFR2 (N550K) and are WT for PTEN. To investigate whether knockdown of FGFR2 induced apoptosis, AN3CA cells were transfected with siRNA targeted toward FGFR2 and labeled with Annexin V-FITC to detect exposed phosphatidylserine by flow cytometry. An increase in Annexin-positivecells was observed.

Knndown of FGFR2 with two independent shRNAs inhibited cell proliferation in both AN3CA and MFE296 cells (Fig. 1A and B), demonstrating the effectiveness of targeting activated FGFR2 even in the presence of PTEN inactivation. As shown in Fig. 1C, shRNA knockdown of FGFR2 resulted in >90% reduction in FGFR2 protein in AN3CA cells and a marked decrease in ERK1/2 phosphorylation. No change in AKT phosphorylation was evident (Fig. 1C).

Figure 2. Endometrial cancer cells with activating FGFR2 mutations are sensitive to PD173074, a pan-FGFR inhibitor. A, PD173074 dose-response curves for six endometrial cancer cell lines. Cell viability was measured with the SRB assay 72 h after addition of PD173074 and data normalized to DMSO (vehicle control) for each cell line. AN3CA and MFE296 cells carry the N550K FGFR2 mutation. HEC1A, Ishikawa, KLE, and RL952 are WT for FGFR2. PD173074 treatment had a profound negative effect on cell viability of cell lines expressing mutant FGFR2 compared with those expressing WT FGFR2. PD173074 IC50 values are as follows: AN3CA, 61.8 nmol/L; MFE296, 284.3 nmol/L; HEC1A, >3000 nmol/L; Ishikawa, 2,920.7 nmol/L; KLE, 3,000 nmol/L; RL952, 3,000 nmol/L. B, Annexin staining reveals cell death of AN3CA cells after treatment with PD173074. AN3CA cells were treated with 0.1% DMSO (vehicle control) or 1 μmol/L PD173074. Forty-eight, 72, or 96 h later, cells were collected and analyzed for Annexin-positive cells by flow cytometry. The dot plots show representative samples after 96 h of PD173074 treatment. PD173074-treated cells showed an increase in Annexin V staining compared with cells treated with DMSO alone, indicative of apoptosis. C, PD173074 leads to G1cell cycle arrest in AN3CA cells. Cells were treated with 1 μmol/L PD173074, and cell cycle analysis was performed by propidium iodide staining and flow cytometry 72 h after addition of PD173074. PD173074 treatment resulted in an accumulation of cells in G1phase of the cell cycle.
staining was evident following transfection with FGFR2 siRNA compared with the nonsilencing siRNA control, indicating that these cells were undergoing apoptosis (Fig. 1D).

Endometrial cancer cells expressing activated FGFR2 are sensitive to PD173074, a pan-FGFR inhibitor. Six endometrial cancer cell lines (two mutant N550K FGFR2 and four WT FGFR2) were treated with increasing concentrations of PD173074, a pan-FGFR tyrosine kinase inhibitor. PD173074 was highly selective for FGFRs in a screen of 224 kinases, inhibiting FGFR1, FGFR2, and FGFR3 at low nanomolar concentrations (12). As shown in Fig. 2A, the two endometrial cancer cell lines with mutant FGFR2 (AN3CA and MFE296) were 10 to 40 times more sensitive to inhibition with PD173074 than cell lines with WT FGFR2. The AN3CA line, which has loss-of-function mutations on both PTEN alleles, was the most sensitive cell line. Annexin V-FITC labeling indicated that ~70% of AN3CA cells were undergoing apoptosis 96 hours after drug treatment (Fig. 2B). In addition, cell cycle analysis revealed that PD173074 treatment induced G1 arrest of AN3CA cells (Fig. 2C).

Activation status of ERK1/2 and AKT after PD173074 treatment. We next evaluated ERK1/2 and AKT activation at various time points after PD173074 treatment. FGFR inhibition resulted in a marked reduction in ERK1/2 activation in AN3CA and MFE296 cells (Fig. 3A). Phosphorylated ERK1/2 began to return 24 to 48 hours after PD173074 treatment but was still below baseline activation at 72 hours. No change in ERK1/2 activation was detectable in HEC1A cells (Fig. 3A), which are WT for FGFR2. PD173074 treatment resulted in a modest reduction in phosphorylated AKT at Threonine 308 and had no effect on phosphorylation of AKT at Serine 473 in HEC1A cells. PD173074 had no effect on phosphorylation of AKT (Threonine 308) in HEC1A cells (13), the image shown here is an overexposure relative to the other pAKT blots presented. AN3CA cells were starved in 0.2% FBS overnight, pretreated with or without 1 μmol/L PD173074 for 1 h, and then stimulated with 1 nmol/L FGF7 and 10 μg/mL heparin for 5 min. Phosphorylation status of FRS2α was assessed by immunoprecipitating with a FRS2α-specific antibody and immunoblotting with a phosphorylation-specific FGFR antibody. The blot was then stripped and reprobed for total FRS2α. Arrow, fully glycosylated, cell surface–expressed, mature receptor. Bottom band, partially glycosylated, immature intracellular receptor. In cells not pretreated with PD173074, phosphorylation of the mature receptor (top band, solid arrow) is evident, with an increase in amount of FRS2α migrating slower than unphosphorylated FRS2α. The change in mobility of FRS2α is due to the phosphorylation status of the protein, with phosphorylated FRS2α migrating slower than unphosphorylated FRS2α (14).

Discussion

Understanding the molecular basis of tumor progression has led to the development and success of targeted therapies in a variety of cancer types. There is increasing evidence that activating mutations in genes involved in various signaling pathways can result in “addiction” of tumor cells to these pathways (15). Furthermore, these activating mutations serve not only to identify potential therapeutic targets, but their presence can also predict clinical response to pathway inhibition (16). However, it has become increasingly clear that the response to target inhibition is also influenced by the molecular context wherein these mutations occur. As we have previously identified activating mutations in FGFR2 in ~16% of endometrioid endometrial tumors (4), here, we sought to investigate the genetic context in which FGFR2 mutations occur in endometrial cancer. We also sought to evaluate the therapeutic potential of targeting activated FGFR2 by investigating the biological consequence of inhibiting FGFR2 in endometrial cancer cells possessing activating mutations in FGFR2.

In the present study, we evaluated the KRAS and PTEN mutation status of endometrioid endometrial tumors with known FGFR2 mutation status. Activating KRAS and FGFR2 mutations did not occur together in the same tumor, consistent with FGFR2 driving...
Inhibition of Activated FGFR2 in Endometrial Cancer

that loss of PTEN may not predict resistance to FGFR inhibitors in endometrial cancer. Interestingly, PD173074 treatment induced cell cycle arrest but did not result in enhanced Annexin V staining in MFE296 cells (data not shown).

Although the mechanism of PD173074-induced cell cycle arrest and apoptosis remains to be fully elucidated, it is intriguing to speculate that these phenotypes may be dependent on inhibition of FGFR-mediated MAPK activation. Consistent with this hypothesis, AN3CA cells are sensitive to MAP/ERK kinase inhibition, with U0126 treatment resulting in Annexin-positive staining similar to that observed with PD173074 (Supplementary Fig. S2).

In summary, we have shown that FGFR2 mutations are coincident with PTEN inactivation and mutually exclusive with KRAS mutations in primary endometrioid endometrial cancers. Blockade of FGFR2 signaling by shRNA knockdown or treatment with a pan-FGFR inhibitor, PD173074, resulted in cell death and cell cycle arrest of endometrial cancer cell lines expressing mutationally activated FGFR2. Together, these data suggest inhibition of constitutively active mutant FGFR2 may be therapeutically beneficial for endometrial cancer patients despite the frequent inactivation of PTEN in this tumor type.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 2/29/2008; revised 6/11/2008; accepted 7/2/2008.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References


www.aacrjournals.org


Downloaded from cancerres.aacrjournals.org on July 24, 2017. © 2008 American Association for Cancer Research.
Correction: Inhibition of Activated FGFR2 in Endometrial Cancer

In the article on inhibition of activated FGFR2 in endometrial cancer in the September 1, 2008 issue of Cancer Research (1), the following grant support information should have been included:

**Grant support:** A V Scholar Grant from The V Foundation for Cancer Research (P.M. Pollock), a Postdoctoral Fellowship PF-07-215-01-TBE from the American Cancer Society (S.A. Byron), and an R01 CA071754 from the NIH (P.J. Goodfellow).

Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation

Sara A. Byron, Michael G. Gartside, Candice L. Wellens, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/17/6902

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2008/08/20/68.17.6902.DC1

Cited articles
This article cites 20 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/17/6902.full#ref-list-1

Citing articles
This article has been cited by 23 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/68/17/6902.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.